# Impact of Treatment With Rituximab on the Progression of Humoral Acute Rejection After Renal Transplantation

> **NCT01350882** · PHASE3 · COMPLETED · sponsor: **University Hospital, Tours** · enrollment: 40 (actual)

## Conditions studied

- Humoral Rejection in Kidney Transplantation

## Interventions

- **DRUG:** MabThera
- **DRUG:** Physiological serum : sodium chloride, sodium citrate

## Key facts

- **NCT ID:** NCT01350882
- **Lead sponsor:** University Hospital, Tours
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10
- **Primary completion:** 2012-10
- **Final completion:** 2012-10
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2025-12-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01350882

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01350882, "Impact of Treatment With Rituximab on the Progression of Humoral Acute Rejection After Renal Transplantation". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01350882. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*